<DOC>
	<DOC>NCT00409409</DOC>
	<brief_summary>A phase III study to evaluate the efficacy and safety of SLIT for grass pollen allergens compared with placebo for reduction of symptoms and rescue medication usage in children.</brief_summary>
	<brief_title>Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Male or female outpatients aged 5 to 17 years. Written consent / assent. Grass pollenrelated allergic rhinoconjunctivitis for at least the last two pollen seasons. Sensitised to grass pollen (positive SPT and grass pollenspecific IgE values of at least Class 2). Total symptom score on the Retrospective RTSS during the previous pollen season of greater than or equal to 12. Patients who have received any desensitisation treatment for grass pollen.</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Sublingual immunotherapy</keyword>
	<keyword>Grass pollen tablet</keyword>
	<keyword>Allergic rhinoconjunctivitis</keyword>
</DOC>